Bone Marrow Harvesting Systems
Bone Marrow Harvesting Systems
Bone Marrow Aspirate collected with the Marrow Cellution™ System has shown a dramatic increase in key stem and progenitor cells when compared to centrifugated marrow from leading systems.
The patent pending Marrow Cellution™ System maximizes the yield of stem and progenitor cells by giving the clinician the ability to efficiently harvest bone marrow from multiple levels within the medullary space, while restricting dilution caused by peripheral blood.
Traditional bone marrow aspiration needles aspirate primarily through an open-ended cannula, which leads to excess peripheral blood dilution and inadequate collection of key stem and progenitor cells. For this reason a high volume of bone marrow aspirate must be collected and then manipulated (i.e. centrifuged) before being utilized for regenerative therapies.
Jamshidi needles were designed to draw very small volumes from multiple insertion points. This technique was subsequently modified by limiting the insertion points and drawing larger volumes (60-240 mL). The aspirate was then reduced through centrifugation due to peripheral blood dilution. This technique delivers low numbers of fibroblastic-like stem cells and is often augmented with expensive allograft alternatives to complete the biologic profile for tissue regeneration.
The patent pending Marrow Cellution™ System overcomes the limitations of a traditional bone marrow needle by allowing the user to aspirate in a measured and controlled manner over a large geography inside the marrow space, while restricting peripheral blood infiltration.
Two unique design features are the key:
The closed-tip aspiration cannula restricts aspiration through the side holes of the cannula and away from the channel caused by the tip of the needle, avoiding excess peripheral blood infiltration.
A mechanical means for measured and controlled retraction of the aspiration cannula allows the clinician to collect marrow aspirate from multiple geographies inside the medullary space with a single puncture.
The Marrow Cellution™ System delivers a better regenerative solution at a reduced cost compared to the industry leading alternatives.
Centrifugation systems typically required 20 minutes or more of spin time during the surgical procedure, not to mention the additional support time needed for preparation and cleanup of the equipment.
Centrifugation systems require passing the BMA off the sterile field for processing, and back on for implantation. The Marrow Cellution™ System eliminates the additional steps where infection concerns must be managed.
Centrifugation systems typically discard 80% of the aspirate due to high levels of peripheral blood. Worse, significant numbers of the desired cells (approx. 40%) are discarded because as these cells increase in density prior to division, they are processed into the undesired red cell centrifuge component and thus discarded, substantially limiting the regenerative potential of the resulting sample.
Centrifugation systems require at least 10% dilution by volume for the addition of anti-coagulant to allow the sample to separate, and also require another 10% dilution in the form of a neutralizing agent such as thrombin and calcium chloride in order for the marrow to clot in the graft. The Marrow Cellution™ System eliminates these requirements.
Protocols require the marrow to be filtered prior to centrifugation. Cells bound within a clot cannot be counted but they can be delivered to the patient when mixed with graft material or injected. This is not the case when clots are filtered out prior to centrifugation. Filtering takes additional time, but more importantly, filtering reduces regenerative potential.
Comparing published results from the leading BMAC competitors against independent real-world clinical usage of the Marrow Cellution™ System demonstrated overwhelming superiority in regenerative potential, as measured by CFU-F per mL.
CFU-F (Colony Forming Unit - Fibroblast) counts are the established metric for measuring the regenerative potential of bone marrow. TNC (total nucleic cell) counts include nucleated red blood cells and white blood cells from the peripheral blood component of the aspirate which have little regenerative capability. Published research consistently use CFU-F counts to identify the thresholds for clinical efficacy.